march 19th tirzepatide FDA Says Compounded Must Exit the Market Eli Lilly launches weight-loss drug
Description
The injection site should be rotated to avoid discomfort and potential skin issues
Our wholistic approach to weight loss delivers sustainable results, boosting your energy and improving your quality of life
In the SURPASS clinical trial program, patients treated with Tirzepatide experienced: HbA1c reductions up to 2.5% Weight loss up to 22.5% of body weight in some trials These numbers surpass those seen in many existing diabetes medications and even some weight loss drugs
Hair thinning is another potential concern during rapid weight loss, though it is more related to the caloric deficit than the medication itself
Many compounded formulations already include B12 or glycine, but additional supplementation may be beneficial depending on your individual needs
